Reactive oxygen species (ROS), a byproduct of cellular metabolism, damage intracellular macromolecules and, when present in excess, can promote normal hematopoietic stem cell differentiation and exhaustion 1-3 . However, mechanisms that regulate the amount of ROS in leukemia-initiating cells (LICs) and the biological role of ROS in these cells are largely unknown. We show here that the ROS low subset of CD44 + cells in T cell acute lymphoblastic leukemia (T-ALL), a malignancy of immature T cell progenitors, is highly enriched in the most aggressive LICs and that ROS accumulation is restrained by downregulation of protein kinase C u (PKC-u). Notably, primary mouse T-ALLs lacking PKC-u show improved LIC activity, whereas enforced PKC-u expression in both mouse and human primary T-ALLs compromised LIC activity. We also show that PKC-u is regulated by a new pathway in which NOTCH1 induces runt-related transcription factor 3 (RUNX3), RUNX3 represses RUNX1 and RUNX1 induces PKC-u. NOTCH1, which is frequently activated by mutation in T-ALL 4-6 and required for LIC activity in both mouse and human models 7,8 , thus acts to repress PKC-u. These results reveal key functional roles for PKC-u and ROS in T-ALL and suggest that aggressive biological behavior in vivo could be limited by therapeutic strategies that promote PKC-u expression or activity, or the accumulation of ROS.
Current therapies for T-ALL are curative in 80% of pediatric cases, but only 40% of adults with T-ALL survive beyond 5 years 9 . The ineffectiveness of chemotherapeutic regimens in both age groups may be attributed to an inability to target LICs [10] [11] [12] , which have increased quiescence, resistance to apoptosis and expression of DNA repair enzymes and drug efflux pumps and are localized within protective or inaccessible niches 13 . More efficient targeting of LICs could thus lead to marked improvements in patient outcomes.
Much recent interest has focused on the role of ROS in normal and malignant stem cell biology 14 . ROS are chemically reactive molecules that participate in self-propagating reactions and, if allowed to accumulate, can cause oxidative damage to intracellular macromolecules, including DNA, proteins and lipids 15, 16 . Normal hematopoietic stem cells are uniquely sensitive to ROS 1-3 , and some cancer stem cells that have low amounts of ROS lose stem activity or become nonviable when the amounts of ROS are increased 17, 18 .
To address the role of ROS in T-ALL, we focused first on LICs in a well-defined mouse model in which mice are reconstituted with syngeneic bone marrow cells that have been transduced with retrovirus encoding ∆E, a constitutively activated form of NOTCH1 lacking the extracellular ligand-binding domain. This approach produces aggressive, serially transplantable T cell leukemias within [8] [9] [10] [11] [12] weeks that are highly similar to human T-ALL [19] [20] [21] . Transplantation of primary NOTCH1-∆E leukemia cells at a limiting dilution into secondary recipients revealed the LIC frequency to be 1 in ~6,100 total cells (95% CI 1 in 2,800-13,200 cells) ( Fig. 1a and Online Methods). Using the cell-permeable indicator dye dichlorodihydrofluorescein diacetate (DCFDA) to assess the amount of intracellular ROS 22 in combination with various surface markers, we noted that the CD44 + fraction contained a subset of cells with low amounts of ROS ( Fig. 1b) . To determine whether LIC activity was asymmetrically distributed within this subpopulation, we prospectively isolated CD44 + ROS low , CD44 + ROS high and CD44 − cell subsets by fluorescence-activated cell sorting (FACS) and injected them into immunocompetent syngeneic (C57BL/6) and immunocompromised nonobese diabetic severe combined immunodeficiency (NOD/SCID) Il2rg −/− (NSG) recipient mice. Notably, the CD44 + ROS low fraction showed substantially enriched LIC activity as compared to the complementary CD44 + ROS high and CD44 − fractions and recapitulated the original tumor heterogeneity ( Fig. 1c and Supplementary  Fig. 1) . Cells sorted only for CD44 expression also showed enriched LIC activity, albeit less so than CD44 + ROS low cells ( Supplementary  Fig. 2) . We obtained similar findings in a second T-ALL model initiated by the G12D mutation of Kras 19 (Fig. 1d) , indicating that enriched LIC activity within the CD44 + ROS low fraction is not confined to the NOTCH1 model.
NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-θ and reactive oxygen species
To assess the relevance of these findings to human disease, we transplanted FACS-sorted ROS high or ROS low subsets of human T-ALL samples into NSG recipients. These samples had previously been expanded in NSG mice 20 to obtain sufficient material for replicate studies. We did not include CD44 in the LIC sorting strategy because most of the xenograft-expanded human samples in our collection already contained high percentages of CD44 + cells (data not shown). Consistent with our observations in mouse models, LIC activity was enriched in the ROS low fraction in the human leukemias ( Fig. 1e) . Taken together, these results show that LICs in both mouse and human T-ALL are characterized by low amounts of ROS.
PKC-θ is a crucial signaling intermediate downstream of the T cell receptor (TCR) and preTCR 23, 24 and is activated in T-ALLs arising in Notch3 intracellular domain (Notch3-IC) transgenic mice 23 . PKC-θ has also been implicated in ROS production in normal T cells 25 . To explore whether PKC-θ might be involved in regulating the amount of ROS in T-ALL cells, we first surveyed PKC-θ expression in the NOTCH1-∆E mouse model. We noted that the amount of PKC-θ protein varied among the primary leukemias ( Fig. 2a ) and that the amounts of PKC-θ and ROS were correlated ( Fig. 2b) . Moreover, T-ALLs generated from PKC-θ null bone marrow 24 had very low amounts of ROS, and restoration of PKC-θ expression by retroviral transduction markedly increased the amount of ROS ( Fig. 2c) . Of note, mature T cells from the spleens of normal PKC-θ null and wildtype mice had similar amounts of ROS ( Supplementary Fig. 3 ), suggesting that the effects of PKC-θ are context dependent. A survey of human T-ALL cell lines and xenograft-expanded human T-ALL samples also revealed varying amounts of PKC-θ protein ( Fig. 2d) . Of note, retroviral PKC-θ expression in HPB-ALL cells (which have low amounts of endogenous PKC-θ) increased the amount of ROS, whereas shRNA-mediated knockdown of PKC-θ in RPMI 8402 cells (which have high amounts of endogenous PKC-θ) decreased the amount of ROS in these cells ( Fig. 2e,f and Supplementary  Figs. 4 and 5) . Taken together, these data support a dominant role for PKC-θ in regulating the amount of ROS in both mouse and human T-ALL.
We next asked whether the low amount of ROS that characterizes the LIC-enriched fractions might be caused by reduced PKC-θ expression. Indeed, LIC-enriched CD44 + and CD44 + ROS low fractions from mouse leukemias had significantly less PKC-θ mRNA and protein than corresponding LIC-depleted CD44 − and CD44 + ROS high fractions, respectively (Fig. 2g,h and Supplementary Fig. 6a,b) . Similarly, LIC-enriched ROS low fractions of human leukemias had significantly less PKC-θ mRNA and protein than corresponding LIC-depleted ROS high fractions (Fig. 2i,j and Supplementary Fig. 6c ). These data suggest that varied expression of PKC-θ contributes to heterogeneous ROS amounts and LIC activities in subpopulations of T-ALL cells.
To address directly the role of PKC-θ in regulating LIC activity, we performed competitive transplants between PKC-θ null and wild-type leukemias, the latter of which had either high or low expression of endogenous PKC-θ. In each case, recipient mice developed leukemias within 3-4 weeks that were composed predominantly of PKC-θ null cells ( Supplementary Fig. 7a ). Of note, we detected a minor population of PKC-θ low cells in some recipients of PKC-θ null plus PKC-θ low cells, as might be expected if increasing PKC-θ 'dose' progressively compromised LIC activity. We also performed competitive transplants between isogenic PKC-θ RV (PKC-θ null cells transduced with retroviral PKC-θ) and parental PKC-θ null cells. The recipient mice all developed leukemias within 3 weeks that were composed almost entirely of PKC-θ null cells ( Fig. 3a,b) , which is consistent with an antagonistic effect of enforced PKC-θ expression on LIC activity. Notably, PKC-θ RV cells produced leukemia under noncompetitive transplant conditions ( Fig. 3a,b) , which excludes a nonspecific toxic effect of enforced PKC-θ expression. In addition, lentiviral expression of a constitutively activated form of PKC-θ 26 in xenograft-expanded human T-ALL cells abrogated LIC activity ( Fig. 3c and Supplementary  Fig. 7b ), again supporting the idea that increasing the PKC-θ dose has increasingly substantial negative effects on LIC activity.
The frequencies of LICs in PKC-θ null and wild-type leukemias were very similar ( Supplementary Fig. 8a,b) , indicating that reduced PKC-θ expression is permissive to, but not sufficient for, LIC activity. Of note, PKC-θ null and wild-type leukemias showed similar latencies Supplementary Table 1 . Throughout the figure, n indicates the number of mice in each group.
npg in both primary and secondary transplant assays ( Supplementary  Fig. 8a-c) , and PKC-θ overexpression or knockdown did not affect cell proliferation ( Supplementary Fig. 8d,e ), arguing against the possibility that leukemias with lower expression of PKC-θ prevail in vivo simply as a result of differential rates of proliferation. Rather, these data support the idea that PKC-θ has a dominant role in determining the ability of T-ALL cells to reconstitute or 'initiate' disease in vivo.
Of note, T-ALL cells with reduced PKC-θ expression or activity showed resistance to chemotherapy and radiation in vitro ( Supplementary  Fig. 9 ), suggesting that low PKC-θ expression or activity might contribute to poor outcome in patients undergoing standard therapy.
To explore how PKC-θ expression is regulated in T-ALL, we examined available microarray data and discovered that the transcription factor RUNX1, which was recently described as a tumor suppressor in T-ALL [27] [28] [29] , was highly correlated with PKC-θ expression in four separate patient cohorts totaling 264 primary samples [30] [31] [32] [33] (Fig. 4a and  Supplementary Fig. 10) . Chromatin immunoprecipitation sequencing (ChIP-Seq) for RUNX1 in the NOTCH1-mutated human T-ALL cell line CUTLL1 revealed four high-confidence RUNX1 binding sites within the PKC-θ locus, one of which was located at the proximal promoter (associated with histone H3 trimethyl Lys4 (H3K4me3) chromatin marks) and three of which were within putative intronic enhancers (associated with H3K4me1 chromatin marks) 34 (Fig. 4b) , suggesting that RUNX1 might regulate PKC-θ expression. Consistent with this idea, shRNA-mediated knockdown of RUNX1 resulted in decreased amounts of PKC-θ mRNA and protein (Fig. 4c,d) .
Given that RUNX3 has been reported to repress RUNX1 in some contexts 35 , we found it notable that ChIP-Seq in CUTLL1 cells 36 revealed two high-confidence NOTCH1 and CBF1/RBPJ-suppressor of hairless-Lag1 (CSL) binding sites located 30-60 kb upstream of the RUNX3 P1 promoter with associated H3K4me1 chromatin marks (Fig. 4e) . This suggested that NOTCH1 might regulate RUNX3 expression, and thus we hypothesized that a transcriptional circuit might be active in T-ALL cells in which NOTCH1 activates RUNX3, RUNX3 represses RUNX1 and RUNX1 activates PKC-θ (Fig. 4f) . In fact, RUNX3 overexpression or knockdown resulted in reciprocal changes in RUNX1 expression, whereas blocking NOTCH by treating cells with γ-secretase inhibitor (GSI) decreased the expression of RUNX3 and increased the expression of RUNX1 and PKC-θ (Fig. 4g,h and Supplementary  Fig. 11a-d) . Dominant-negative mastermind-like 1 (DN-MAML) 37 recapitulated the effects of GSI on RUNX3, confirming that these effects are specific to NOTCH signaling (Supplementary Fig. 11e,f) . Furthermore, GSI treatment caused the amounts of ROS to increase, a response that did not occur in PKC-θ null mouse leukemias and was npg l e t t e r s nature medicine VOLUME 18 | NUMBER 11 | NOVEMBER 2012 1 6 9 7
abrogated by PKC-θ inhibition or RUNX1 knockdown in human T-ALL cells ( Fig. 4i and Supplementary Fig. 12 ). Despite these effects, PKC-θ null leukemia cells remained sensitive to GSI-induced growth arrest in vitro 6, 20, 37 (Supplementary Fig. 13) . These results reveal a previously unknown mechanism connecting NOTCH1 to LIC activity though negative regulation of PKC-θ expression, thus resulting in reduced amounts of intracellular ROS, and are consistent with prior studies showing that NOTCH1 promotes LIC activity 7, 8 . Of note, we also observed NOTCH1 to contribute to regulation of CD44 expression ( Supplementary Fig. 14) , further supporting its role in defining LICs. Variation among individual cell lines suggests that other factors probably impinge on components of the NOTCH1-RUNX3-RUNX1-PKC-θ transcriptional circuit; however, the overall consistent effects support the relevance of these results. Prior studies have identified mouse T-ALL LICs to be enriched in either the c-Kit mid CD3 + fraction (VEC-Cre/PTEN null model) 38 or the CD4 − CD8 − (double negative or DN) fraction (SIL-SCL/Lck-LMO1 model) 39 . In the NOTCH1-∆E model used here, we found LICs to be enriched in the CD44 + ROS low fraction but to show variable expression of CD4 and CD8 (Supplementary Fig. 15 ). Further studies will be needed to determine to what extent these LIC-containing populations overlap and how different oncogenes affect LIC identity. Our findings suggest that PKC-θ may have a broad role in regulating LIC activity in T-ALL. Although the identified pathway linking NOTCH1 and PKC-θ is probably most relevant in tumors with activating NOTCH1 (ref. 6) or inactivating F-box and WD-40 domain protein 7 (FBW7) 4,5 mutations, PKC-θ expression may be similarly reduced in tumors with loss-of-function RUNX1 mutations (recently reported to occur in 4-18% of T-ALLs [27] [28] [29] or elevated expression of RUNX3 or by mechanisms that are independent of NOTCH1 and RUNX. Alternatively, cell signaling events that modulate PKC-θ activity rather than expression per se 40 may also have important effects on LIC activity. Further studies will be required to explore the intriguing possibility that therapies that promote PKC-θ expression, activity or both may antagonize LICs and thereby improve clinical outcomes in patients with T-ALL.
MeTHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
ONLINe MeTHODS
Mice. PKC-θ (Prkcq) knockout mice (backcrossed over ten generations to C57BL/6) have been described previously 24 . We obtained C57BL/6 (Ly5.2), B6.SJL-Ptprc a Pepc b /BoyJ (Ly5.1) and NSG mice from in-house colonies maintained at the British Columbia Cancer Agency (BCCA) Animal Resource Centre. We housed all mice in specific pathogen-free facilities according to institutional guidelines. All breeding and animal experiments were performed under protocols approved by the University of British Columbia (UBC) Animal Care Committee and according to guidelines of the Canadian Council on Animal Care.
Viruses. We produced high-titer, replication-defective retroviral supernatants by transient transfection of PlatE cells 41 and produced lentivirus by transient cotransfection of 293T cells with packaging and envelope vectors, as previously described 42 . Murine stem cell virus (MSCV)-based retroviral expression vectors encoding constitutively active NOTCH1 (∆E or L1601P-∆PEST alleles) with internal ribosomal entry site (IRES)-GFP or IRES-truncated NGFR (tNGFR) cassettes for tagging of transduced cells have been described 19, 21, 37 . We constructed similar retroviral expression vectors carrying wild-type PKC-θ complementary DNA (cDNA). The DN-MAML retroviral construct encoding amino acids 13-74 of human MAML1 fused to GFP has been previously described 37 . We expressed RUNX3 and constitutively activated PKC-θ (with the A148E mutation) 26 cDNAs from the lentiviral vector pRRL-cPPT/CTS-MNDU3-PGK-GFP-WPRE, which is composed of the pRRLsin-18 backbone 43, 44 , central polypurine tract (cPPT) with central DNA flap 45, 46 , modified myeloproliferative sarcoma virus long terminal repeat U3 region (MNDU3) promoter 47, 48 , phosphoglycerate kinase (PGK)-GFP marker and woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (plasmid construction details available on request). We cloned the RNAi Consortium (TRC) shRNAs 49 targeting PKC-θ (shPKC-θ-91, TRCN0000001791; shPKC-θ-92, TRCN0000001792), RUNX1 (shRUNX1-58, TRCN0000013658; shRUNX1-59, TRCN0000013659) and RUNX3 (shRUNX3, TRCN0000235674) into the pLKO.1puro lentivector, as previously described 50 . We obtained the scrambled shRNA control (shScramble) in pLKO.1puro vector from Addgene (1864) 51 . We verified all constructs by sequencing. We isolated virally transduced cells by FACS or by selection with puromycin, as applicable.
Bone marrow transplantation.
To generate primary mouse leukemias, we transduced bone marrow cells from 5-fluorouracil-treated mice (C57BL/6 background) with retrovirus by spinoculation 20 . Three days later, we injected 10,000-40,000 GFP + or NGFR + cells (including at least 1 × 10 5 normal bone marrow cells) into the tail veins of lethally irradiated (810 rad) C57BL/6 recipients. For serial transplantation experiments, we injected varying numbers of total or FACS-sorted primary leukemia cells by tail vein into nonirradiated C57BL/6 or sublethally irradiated (200 rad) NSG secondary recipient mice. We monitored all transplant recipient mice daily for clinical signs of leukemia. We also followed the leukemia engraftment and progression in some recipients with periodic peripheral blood sampling and flow cytometric analysis.
Human samples. We obtained all human samples with appropriate institutional approvals (UBC/BCCA Research Ethics Board, Institutional Review Board of the Institut Universitaire d'Hématologie/Université Paris Diderot, Karmanos Cancer Center Institutional Review Board and MD Anderson Cancer Center Institutional Review Board) and informed consent under guidelines established by the Declaration of Helsinki. We isolated mononuclear cells from fresh bone marrow aspirate or peripheral blood samples by density gradient centrifugation and used them directly or cryopreserved them. Subsequent analyses used human-specific antibodies against CD45 (1:20, HI30), CD3 (1:20, OKT3), CD4 (1:20, OKT4), CD8 (1:20, RPA-T8) and/or CD44 (1:100, IM7) (eBioscience) to discern human T-ALL lymphoblasts.
Cell culture. All established cell lines have been reported previously 6, 52, 53 . We cultured these cell lines in RPMI 1640 medium supplemented with 10% FCS, 1 mM sodium pyruvate, 2 mM l-glutamine and antibiotics. We isolated primary mouse leukemia cells from the bone marrow or spleen of moribund mice and, where indicated, cultured them briefly in vitro in complete media as described above with the supplemental cytokines interleukin-2 (IL-2) and IL-7, each at 10 ng ml −1 (Peprotech). We expanded primary human T-ALL lymphoblasts as xenografts in sublethally irradiated NSG mice and, where indicated, cultured them briefly in vitro on MS5/MS5-DL1 feeders 7 or immobilized Ig-DL1 ligand 54 , as previously described 20 .
To inhibit PKC-θ enzymatic activity, we treated cells in vitro with 5 µM myristoylated PKC-θ pseudosubstrate inhibitor (539636, Calbiochem). To inhibit Notch signaling, we treated cells in vitro with 1 µM GSI XXI (compound E; ALX-270-415, Alexis). To reduce the amounts of ROS directly, we treated cells in vitro with the vitamin E-derivative antioxidant, Trolox (Calbiochem), at 50 µM final concentration.
We achieved doxycycline-inducible expression of DN-MAML 37 by lentiviral transduction of cells with pLVX-Tet-On Advanced (Clontech, CMV-IE promoter replaced with EF1-α promoter) followed by selection in G418 and then with DN-MAML in pLVX-Tight-Puro (Clontech) followed by selection in puromycin. Cells were treated with 500 ng ml −1 doxycycline for 4 d prior to assay.
Chemotherapy and radiation resistance assays. To assess drug sensitivity in vitro, we plated cells at ~7.5 × 10 5 cells ml −1 per well in 24-well dishes, treated them with doxorubicin (5 µg ml −1 for primary mouse leukemias or 2 µg ml -1 for human cell lines) or dexamethasone (10 µg ml -1 for primary mouse leukemias or 100 µg ml -1 for human cell lines) and then assayed them 48-72 h later. To assess radiation sensitivity in vitro, we plated cells at ~7.5 × 10 5 cells ml -1 per well in 24-well dishes, treated them with X-irradiation using a single 10-Gy dose and then assayed them 48-72 h later. We measured cell viability in each case by flow cytometry for exclusion of propidium iodide. To assess DNA damage in vitro, we plated cells at ~7.5 × 10 5 cells ml −1 per well in 24-well dishes, treated them with X-irradiation using a single 1-Gy dose and then analyzed them for phosphorylated histone H2A.X by flow cytometry 1 h later.
Flow cytometry. We stained mouse leukemia cells with fluorochrome or biotin-conjugated antibodies against CD45.1 (1:100, A20), CD45.2 (1:100, 104), CD3 (1:100, 145-C11), CD4 (1:100, GK1.5 or RM4-5), CD8 (1:100, 53-6.7) and CD44 (1:100, IM7) (eBioscience, Biolegend). We used antibodies to human CD271 (1:50, 130-091, Miltenyi Biotec) to detect the retroviral NGFR marker. We performed intracellular staining with antibodies to PKC-θ (1:5, 560216, BD Biosciences), RUNX3 (1:40, MAB3765, R&D Systems) and phosphorylated histone H2A.X (Ser139) (1:50, 9718, Cell Signaling) after paraformaldehyde fixation and permeabilization with 90% ice-cold methanol (for PKC-θ and H2A.X) or saponin (for RUNX3), as specified by the manufacturer. Where applicable, we also used fluorochromeconjugated secondary antibodies (1:100 dilution, Biolegend). To assess ROS concentrations, we stained live cells with 5-(and-6)-carboxy-2′,7′-DCFDA (carboxy-H 2 -DCFDA), dihydroethidine (DHE) or Mitosox, according to the manufacturer's instructions (Invitrogen). We measured cell proliferation by BrdU incorporation according to the manufacturer's instructions (BrdU kit, BD Biosciences). We measured cell viability by propidium iodide exclusion. We performed FACS analysis and sorting on FACS Calibur, Canto2, Vantage DiVa and Aria2 cytometers (BD Biosciences). We analyzed flow cytometry data using FlowJo software (TreeStar).
Quantitative RT-PCR. We extracted total RNA after cell lysis in TRIzol reagent (Invitrogen). We generated first-strand cDNA by reverse transcription with SuperScript III (Invitrogen) using a mix of random 15-mer and anchored oligo(dT) primers and then amplified the product by real-time PCR using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and a Bio-Rad Chromo4 optical detector. Specific primer sequences are available on request. We assayed each sample in triplicate and calculated expressions by the ∆∆Ct method with normalization to β-actin.
Western blot and immunofluorescence. To generate whole-cell lysates, we washed cells in ice-cold PBS and then lysed them in ice-cold 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium deoxycholate, 150 mM sodium chloride, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride and npg
